TrialJournal for immunotherapy of cancer2023

Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.

Cecilia Monge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.